TW201919642A - 19去甲c3,3-二取代之c21-n-吡唑類固醇及其使用方法 - Google Patents
19去甲c3,3-二取代之c21-n-吡唑類固醇及其使用方法 Download PDFInfo
- Publication number
- TW201919642A TW201919642A TW107132510A TW107132510A TW201919642A TW 201919642 A TW201919642 A TW 201919642A TW 107132510 A TW107132510 A TW 107132510A TW 107132510 A TW107132510 A TW 107132510A TW 201919642 A TW201919642 A TW 201919642A
- Authority
- TW
- Taiwan
- Prior art keywords
- compound
- sleep
- individual
- administered
- effective amount
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Anesthesiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762558703P | 2017-09-14 | 2017-09-14 | |
| US62/558,703 | 2017-09-14 | ||
| US201862624680P | 2018-01-31 | 2018-01-31 | |
| US201862624678P | 2018-01-31 | 2018-01-31 | |
| US62/624,680 | 2018-01-31 | ||
| US62/624,678 | 2018-01-31 | ||
| US201862653189P | 2018-04-05 | 2018-04-05 | |
| US62/653,189 | 2018-04-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW201919642A true TW201919642A (zh) | 2019-06-01 |
Family
ID=65723895
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW107132510A TW201919642A (zh) | 2017-09-14 | 2018-09-14 | 19去甲c3,3-二取代之c21-n-吡唑類固醇及其使用方法 |
| TW111150395A TW202339764A (zh) | 2017-09-14 | 2018-09-14 | 19去甲c3,3-二取代之c21-n-吡唑類固醇及其使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW111150395A TW202339764A (zh) | 2017-09-14 | 2018-09-14 | 19去甲c3,3-二取代之c21-n-吡唑類固醇及其使用方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US20220110949A1 (enExample) |
| EP (3) | EP4218767A1 (enExample) |
| JP (3) | JP2020534270A (enExample) |
| AU (2) | AU2018334214A1 (enExample) |
| CA (1) | CA3075872A1 (enExample) |
| IL (2) | IL303083A (enExample) |
| MX (3) | MX2020002889A (enExample) |
| TW (2) | TW201919642A (enExample) |
| WO (1) | WO2019055764A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201606063RA (en) | 2012-01-23 | 2016-09-29 | Sage Therapeutics Inc | Neuroactive steroid formulations and methods of treating cns disorders |
| RS62761B1 (sr) | 2012-08-21 | 2022-01-31 | Sage Therapeutics Inc | Alopregnanolon za lečenje refraktornog epileptičkog statusa |
| SMT202100509T1 (it) | 2013-04-17 | 2021-11-12 | Sage Therapeutics Inc | Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia |
| US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| WO2016082789A1 (en) | 2014-11-27 | 2016-06-02 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| WO2018013613A1 (en) | 2016-07-11 | 2018-01-18 | Sage Therapeutics, Inc. | C17, c20, and c21 substituted neuroactive steroids and their methods of use |
| TW202604538A (zh) | 2016-08-23 | 2026-02-01 | 美商賽吉醫療公司 | 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇 |
| US20200291059A1 (en) | 2017-12-08 | 2020-09-17 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| US10857163B1 (en) | 2019-09-30 | 2020-12-08 | Athenen Therapeutics, Inc. | Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof |
| US20230018765A1 (en) * | 2019-12-05 | 2023-01-19 | Sage Therapeutics, Inc. | A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SMT202100509T1 (it) * | 2013-04-17 | 2021-11-12 | Sage Therapeutics Inc | Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia |
| US20170233433A1 (en) * | 2014-10-16 | 2017-08-17 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| TW202604538A (zh) * | 2016-08-23 | 2026-02-01 | 美商賽吉醫療公司 | 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇 |
| EP3678670A1 (en) * | 2017-09-07 | 2020-07-15 | Sage Therapeutics, Inc. | Neuroactive steroids and their methods of use |
-
2018
- 2018-09-14 US US16/647,203 patent/US20220110949A1/en not_active Abandoned
- 2018-09-14 EP EP23150618.9A patent/EP4218767A1/en not_active Withdrawn
- 2018-09-14 EP EP25207758.1A patent/EP4696301A3/en active Pending
- 2018-09-14 IL IL303083A patent/IL303083A/en unknown
- 2018-09-14 WO PCT/US2018/051048 patent/WO2019055764A1/en not_active Ceased
- 2018-09-14 JP JP2020514950A patent/JP2020534270A/ja active Pending
- 2018-09-14 TW TW107132510A patent/TW201919642A/zh unknown
- 2018-09-14 CA CA3075872A patent/CA3075872A1/en active Pending
- 2018-09-14 EP EP18786464.0A patent/EP3681510A1/en not_active Withdrawn
- 2018-09-14 MX MX2020002889A patent/MX2020002889A/es unknown
- 2018-09-14 AU AU2018334214A patent/AU2018334214A1/en not_active Abandoned
- 2018-09-14 TW TW111150395A patent/TW202339764A/zh unknown
-
2020
- 2020-03-08 IL IL273126A patent/IL273126A/en unknown
- 2020-03-13 MX MX2023010064A patent/MX2023010064A/es unknown
- 2020-03-13 MX MX2023010063A patent/MX2023010063A/es unknown
-
2023
- 2023-01-24 JP JP2023008782A patent/JP2023038310A/ja active Pending
- 2023-03-01 US US18/176,571 patent/US20230201224A1/en not_active Abandoned
-
2024
- 2024-06-05 JP JP2024091642A patent/JP2024107137A/ja not_active Withdrawn
- 2024-08-07 AU AU2024205601A patent/AU2024205601A1/en active Pending
-
2025
- 2025-05-08 US US19/202,525 patent/US20250387414A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20250387414A1 (en) | 2025-12-25 |
| JP2023038310A (ja) | 2023-03-16 |
| MX2023010063A (es) | 2023-09-06 |
| EP4218767A1 (en) | 2023-08-02 |
| EP3681510A1 (en) | 2020-07-22 |
| CA3075872A1 (en) | 2019-03-21 |
| JP2020534270A (ja) | 2020-11-26 |
| MX2023010064A (es) | 2023-09-06 |
| EP4696301A3 (en) | 2026-04-29 |
| AU2024205601A1 (en) | 2024-08-29 |
| MX2020002889A (es) | 2020-10-01 |
| EP4696301A2 (en) | 2026-02-18 |
| WO2019055764A1 (en) | 2019-03-21 |
| US20230201224A1 (en) | 2023-06-29 |
| JP2024107137A (ja) | 2024-08-08 |
| IL303083A (en) | 2023-07-01 |
| IL273126A (en) | 2020-04-30 |
| AU2018334214A1 (en) | 2020-03-26 |
| TW202339764A (zh) | 2023-10-16 |
| US20220110949A1 (en) | 2022-04-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250387414A1 (en) | 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof | |
| CN114340670B (zh) | T-型钙通道调节剂的制剂及其使用方法 | |
| AU2015336463B2 (en) | Compositions and methods for treating insomnia | |
| TW201740952A (zh) | 晝夜節律睡眠障礙之治療方法 | |
| KR20230018384A (ko) | T-형 칼슘 채널 조정제의 사용 방법 | |
| TWI802623B (zh) | 一種(6S)-N-[4-({(2S,5R)-5-[(R)-羥基(苯基)甲基]吡咯啶-2-基}甲基)苯基]-4-側氧-4,6,7,8-四氫吡咯并[1,2-a]嘧啶-6-甲醯胺用於夜間頻尿治療劑之醫藥製造之用途 | |
| JP2025542596A (ja) | 乳分泌中の女性にソルリアムフェトルを投与する方法 | |
| KR20250165616A (ko) | 고함량 단일 투여 단위 제형 및 이의 사용 방법 | |
| HK40096830A (en) | A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof | |
| US20220305012A1 (en) | Lemborexant for treating sleep issues | |
| JP2025514644A (ja) | 痙縮を治療するための化合物及び方法 | |
| RU2844395C2 (ru) | Лемборексант для лечения проблем со сном | |
| EP3989976A1 (en) | Lemborexant for treating sleep issues | |
| WO2020263331A1 (en) | Lemborexant for treating sleep issues | |
| JP2025116005A (ja) | 睡眠問題の治療のためのレンボレキサント | |
| JP2025536721A (ja) | 強迫性障害の予防または治療のための低用量のドネペジルまたはその誘導体を使用した新規投与レジメン | |
| AU2024238367A1 (en) | Method for treating l-dopa-induced dyskinesia using befiradol | |
| TW202508553A (zh) | 用於預防、減緩或治療睡眠障礙及／或與睡眠障礙相關之疾病的方法 | |
| CA2885570C (en) | Methods for treating post-traumatic stress disorder | |
| Parkes et al. | Disorders of Sleep and Wakefulness | |
| HK1145282B (en) | Treatment of sleep disorders | |
| HK1145282A1 (en) | Treatment of sleep disorders |